MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

2016 International Congress

June 19-23, 2016. Berlin, Germany.

View by Title View Sessions
View by Date

Tuesday, June 21, 2016

12:30pm-2:00pm
Mild mitochondrial impairment promotes corticostriatal synaptic plasticity alterations in PINK1 heterozygous knockout mice

P. Imbriani, G. Martella, G. Madeo, M. Maltese, V. Vanni, E. Ferraro, E.M. Valente, T. Schirinzi, L. Bonanni, J. Shen, N.B. Mercuri, P. Bonsi, A. Pisani (Rome, Italy)

Parkinson's disease: Pathophysiology  ·  Exhibit Hall located in Hall B, Level 2
12:30pm-2:00pm
Minimum MDS-UPDRS part III change needed to convert a Parkinson’s disease patient from the OFF to full ON state with apomorphine sublingual film (APL-130277)

H. Shill, A. Agro, E.J. Pappert, B. Dzyngel, T. Bilbault, S. Isaacson, R. Hauser (Phoenix, AZ, USA)

Parkinson's disease: Pathophysiology  ·  Exhibit Hall located in Hall B, Level 2
12:30pm-2:00pm
Mitochondrial cardiolipin couples electron transport between ubiquinone and complex I to rescue PINK1 deficiency

M. Vos, A. Geens, L. Deaulmerie, J. Swerts, K. Craessaerts, P. Seibler, A. Rakovic, B. De Strooper, R. Efremov, V.A. Morais, C. Klein, P. Verstreken (Lübeck, Germany)

Parkinson's disease: Genetics  ·  Exhibit Hall located in Hall B, Level 2
12:30pm-2:00pm
Mitochondrial dysfunction in skin fibroblasts from single heterozygous ATP13A2 (PARK9) mutation carriers

J.S. Park, C. Klein, C.M. Sue (St. Leonards, Australia)

Parkinson's disease: Pathophysiology  ·  Exhibit Hall located in Hall B, Level 2
12:30pm-2:00pm
Mitochondrial Hsp90 inhibitor G-TTP triggers PINK1/parkin-dependent mitochondrial quality control

F.C. Fiesel, J.D. Elle, H.R. Anneliese, H. Roman, S. Wolfdieter (Jacksonville, FL, USA)

Parkinson's disease: Pathophysiology  ·  Exhibit Hall located in Hall B, Level 2
12:30pm-2:00pm
Mitochondrial response precedes intracellular accumulation of α-synuclein in Parkinson’s disease

I. Milenkovic, E. Dassler, M. Weber, G.G. Kovacs (Vienna, Austria)

Parkinson's disease: Pathophysiology  ·  Exhibit Hall located in Hall B, Level 2
12:30pm-2:00pm
Mitochondrial-nuclear interplay in single respiratory chain-deficient Parkinson’s disease neurons

A. Grünewald, K.A. Rygiel, P.D. Hepplewhite, C.M. Morris, M. Picard, D.M. Turnbull (Belvaux, Luxembourg)

Parkinson's disease: Pathophysiology  ·  Exhibit Hall located in Hall B, Level 2
12:30pm-2:00pm
Mixed tremor with cryptogenic atrophy of dominant hemisphere, diagnostic and treatment challenges

O.E. Turgunkhujaev, A.R. Khashimova (Tashkent, Uzbekistan)

Tremor  ·  Exhibit Hall located in Hall B, Level 2
12:30pm-2:00pm
Modulating neuronal activity in dopaminergic neurons to promote their survival

M.A. Bernardi, N. Baffa-Trasci, O. Gershanik, M.E. Avale, J.E. Ferrario (Caba, Argentina)

Parkinson's disease: Pathophysiology  ·  Exhibit Hall located in Hall B, Level 2
12:30pm-2:00pm
Modulation of microglia function in the prion-like spreading of α-synuclein in the murine brain

W.M. Wemheuer, P. Garcia, E. Konica, A. Masuch, S. Brioschi, K. Biber, A. Weihofen, H. Kollmus, K. Schughart, D. Coowar, R. Balling, M. Buttini (Esch-sur-Alzette, Luxembourg)

Parkinson's disease: Pathophysiology  ·  Exhibit Hall located in Hall B, Level 2
  • «Previous Page
  • 1
  • …
  • 27
  • 28
  • 29
  • 30
  • 31
  • …
  • 48
  • Next Page»

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Welcome to the MDS Abstracts Site
  • Life expectancy with and without Parkinson’s disease in the general population
  • Nilotinib for treating MSA: A preclinical proof of concept study
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley